• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1111913 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- A2 ?, W4 ?7 O" q* x& D
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 - m, T& [& r9 Y5 v( n
+ Author Affiliations% E( V( S1 p& ?- _
$ c! \3 t3 I4 V+ C# s7 I' Q& z
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 T8 K9 X. a  Z, J' j2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" Z' V& A& a2 }% j2 D3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan : i9 U! ]' F( M' K
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
6 w" j% y; ~8 Q/ T1 Q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, C) s8 q# v; F2 ^% X/ Z& x- q6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 1 \, \) ]8 j  x+ O, H
7Kinki University School of Medicine, Osaka 589-8511, Japan ; Q& A( y' W5 u9 J, y' [
8Izumi Municipal Hospital, Osaka 594-0071, Japan 8 i) i( d) S/ b& H
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan # V4 Y8 d7 ~2 j/ i) L7 }
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
0 h( x, R" c( `6 ?- Y* xAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* B% s" z6 P4 k2 D8 x" H1 g- C: h! P1 l0 p" v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
8 c: y! `# u3 o0 Q# ^* v& E! L/ h5 r" x/ N+ A
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 7 j9 A4 }% M8 D$ f! Y8 B
) v) I3 r8 M2 }9 u$ Y
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
8 M0 W0 r, m1 b. F) w; g2 d. [; @/ V" G
Published online on: Thursday, December 1, 2011 3 m# {0 N; a$ C2 o" W$ ~

& T. y9 I2 t; K$ {* QDoi: 10.3892/ol.2011.507 : [$ Y: D, c/ I, S' U9 d. x
0 ]) b/ l) S- k; I/ F& u  b
Pages: 405-410 1 N" |/ P( s) P9 m

: ^7 e- ]! w' r8 C, j2 WAbstract:) J% u$ Z- V; d( A9 j* X
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.0 K: I2 T" \3 P5 g2 j) \1 e

6 M  n7 T) ~% V* _
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
9 F1 T/ G# Q* E8 n0 ?F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 : t# D4 f$ W0 y- N6 C! ?* q
+ Author Affiliations
8 e# S- B/ I) S' R1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu , H, {3 u( Y/ f
2Department of Thoracic Surgery, Kyoto University, Kyoto 0 t- V" l3 V3 r  f. g3 `' k+ x, \
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan ( f4 H7 P; P5 x& p. q7 l+ f. E
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 3 E6 e$ \5 F  s3 ?
Received September 3, 2010.
7 _/ T3 o: }0 A# w( YRevision received November 11, 2010.
% r, u, ]  N; u2 s' |Accepted November 17, 2010. + C+ b" h3 m- F% @2 Y& ?/ b, u
Abstract
) g8 S4 k7 d( t5 iBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 3 {. Q) o8 ^' Y9 R! t, ]1 Z; b! G
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 3 {2 R/ ^1 `- O
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
; @0 a( l0 a5 L# p' \Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
. T% L- ]6 f. M! z& W% L2 Y" G) S0 D
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
- n) C( O; N  e& y- L3 t今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
4 A' j  V. P2 Q( a. ]( q
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
5 `/ T- D, _! j! D/ ehttp://clinicaltrials.gov/ct2/show/NCT01523587- t/ J6 c$ H. u! y
  z5 u+ l0 b! t' j0 L* B
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC- X' P" i* D  p2 D5 g+ W/ P
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 ! C% w0 Q( z5 [! p% g+ f- `

/ o: c* q; U) C从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。! F  ]) `! Z" _; R; m9 m3 O
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 " J7 U) Q3 v' C. Y
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
" a( G, Z% ?% [# a, C5 x至今为止,未出 ...

  K: u6 V7 \8 |$ i没有副作用是第一追求,效果显著是第二追求。" ]% L% T0 \1 ?; E2 u
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表